CD8A and neoplasm: We sorted tumor-infiltrating CD8+ T cells (TI-CD8+) from subcutaneous (s.c.)Myc-CaP tumors, treated with either Oxali, anti–PD-L1, Oxali + anti–PD-L1 (combo), or left untreated (control [Ctrl]) and performed single-cell (sc)RNA-seq (Fig. 7A and SI Appendix, Fig. S14A).